Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2626 to 2640 of 8952 results

  1. Endovascular Arch Repair

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  2. Endovascular stent insertion for intracranial atherosclerotic disease

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  3. Lutetium (177Lu) oxodotreotide for treating SSTR-positive advanced or inoperable gastroenteropancreatic neuroendocrine tumours in people 12 to 17 years [TSID12154]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  4. Subcutaneous nivolumab–relatlimab for untreated unresectable or metastatic melanoma in people 12 years and over [TSID 12178]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  5. CADScor system for ruling out coronary artery disease in people with symptoms of stable coronary artery disease (MT434

    Topic prioritisation

    Diagnostics guidance
    Topic prioritisation

  6. Cor-Knot for tying suture knots in valve surgery

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  7. Treprostinil for treating symptomatic chronic thromboembolic pulmonary hypertension [ID3926 ]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  8. Heart valve disease presenting in adults: investigation and management - transcatheter aortic valve implantation (TAVI) to treat aortic stenosis (update)

    In development Reference number: GID-NG10457 Expected publication date: TBC

    NICE guideline
    In development

  9. V940 with pembrolizumab for adjuvant treatment of resected high-risk stage 2 to 4 melanoma [ID6674]

    Awaiting development Reference number: GID-TA11881 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Belzutifan with pembrolizumab for adjuvant treatment of clear cell renal cell carcinoma after nephrectomy [ID6645]

    Awaiting development Reference number: GID-TA11813 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Belzutifan with pembrolizumab and lenvatinib for untreated advanced clear cell renal cell carcinoma [ID6605]

    Awaiting development Reference number: GID-TA11751 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Belzutifan with lenvatinib for treating advanced renal cell carcinoma after a PD-1 or PD-L1 inhibitor [ID6476]

    Awaiting development Reference number: GID-TA11584 Expected publication date:  08 December 2027

    Technology appraisal guidance
    Awaiting development

  13. Apalutamide with radical prostatectomy for untreated high-risk, localised or locally advanced prostate cancer [ID6471]

    Awaiting development Reference number: GID-TA11490 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Larotrectinib for treating NTRK fusion-positive advanced solid tumours (MA review of TA630) [ID6292]: draft guidance

    We are listening to your views on this Technology appraisal guidance. Comments close 24 April 2026.

    Technology appraisal guidance
    In consultation

  15. Suspected sepsis in pregnancy: recognition, diagnosis and early management

    In development Reference number: GID-NG10468 Expected publication date:  17 February 2027

    NICE guideline
    In development